NO20035352L - Legemidler for eosinofile sykdommer - Google Patents

Legemidler for eosinofile sykdommer

Info

Publication number
NO20035352L
NO20035352L NO20035352A NO20035352A NO20035352L NO 20035352 L NO20035352 L NO 20035352L NO 20035352 A NO20035352 A NO 20035352A NO 20035352 A NO20035352 A NO 20035352A NO 20035352 L NO20035352 L NO 20035352L
Authority
NO
Norway
Prior art keywords
medicines
eosinophilic diseases
eosinophilic
diseases
Prior art date
Application number
NO20035352A
Other languages
English (en)
Other versions
NO20035352D0 (no
Inventor
Kenju Miura
Maki Matsubayashi
Hirohisa Saito
Kenji Matsumoto
Original Assignee
Daiichi Suntory Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Suntory Pharma Co Ltd filed Critical Daiichi Suntory Pharma Co Ltd
Publication of NO20035352D0 publication Critical patent/NO20035352D0/no
Publication of NO20035352L publication Critical patent/NO20035352L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20035352A 2001-06-22 2003-12-01 Legemidler for eosinofile sykdommer NO20035352L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001190083 2001-06-22
PCT/JP2002/006219 WO2003000286A1 (fr) 2001-06-22 2002-06-21 Remedes pour maladies eosinophiliques

Publications (2)

Publication Number Publication Date
NO20035352D0 NO20035352D0 (no) 2003-12-01
NO20035352L true NO20035352L (no) 2004-02-19

Family

ID=19028907

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035352A NO20035352L (no) 2001-06-22 2003-12-01 Legemidler for eosinofile sykdommer

Country Status (11)

Country Link
US (1) US20040156847A1 (no)
EP (1) EP1405645A4 (no)
JP (1) JPWO2003000286A1 (no)
CN (1) CN1518459A (no)
AU (1) AU2002315848B2 (no)
BR (1) BR0210578A (no)
CA (1) CA2451138A1 (no)
IL (1) IL159478A0 (no)
NO (1) NO20035352L (no)
NZ (1) NZ530001A (no)
WO (1) WO2003000286A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1667730T3 (da) * 2003-08-20 2013-09-23 Univ Miami Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom
BRPI0607203A2 (pt) * 2005-02-18 2009-08-25 Medarex Inc anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
CA2605508A1 (en) * 2005-05-12 2006-11-23 Wisconsin Alumni Research Foundation Blockade of pin1 prevents cytokine production by activated immune cells
CA2621083C (en) 2005-08-30 2017-04-11 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
CN102770455B (zh) 2009-08-03 2017-02-08 迈阿密大学 用于体内扩增调节性t细胞的方法
WO2013119990A2 (en) * 2012-02-10 2013-08-15 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
JP2016504045A (ja) 2013-01-09 2016-02-12 ザ ユニバーシティー オブ マイアミＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ ＴＬ１Ａ−Ｉｇ融合タンパク質を用いる制御性Ｔ細胞の制御のための組成物及び方法
KR101611743B1 (ko) * 2014-10-28 2016-04-11 인제대학교 산학협력단 모세기관지염 후 천식 진단을 위한 마커 및 이의 용도
CN110361546A (zh) * 2019-08-28 2019-10-22 重庆三峡医药高等专科学校 一种检测嗜酸性粒细胞阳离子蛋白的胶体金试纸条

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
WO1993024135A1 (en) * 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
CA2380009A1 (en) * 1999-07-28 2001-02-08 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclastogenesis

Also Published As

Publication number Publication date
CN1518459A (zh) 2004-08-04
NZ530001A (en) 2006-08-31
IL159478A0 (en) 2004-06-01
WO2003000286A1 (fr) 2003-01-03
EP1405645A4 (en) 2005-02-02
US20040156847A1 (en) 2004-08-12
JPWO2003000286A1 (ja) 2004-10-07
AU2002315848B2 (en) 2008-05-15
EP1405645A1 (en) 2004-04-07
BR0210578A (pt) 2004-08-10
NO20035352D0 (no) 2003-12-01
CA2451138A1 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
NO20033556D0 (no) Farmasöytiske preparater
EE200300416A (et) Ravimvorm
NO20033143D0 (no) Farmasoytisk preparat
PT1501534E (pt) Formulacoes farmaceuticas
FI20011478A0 (fi) Farmaseuttinen koostumus
DK1383560T4 (da) Infusionssæt
NO20035315D0 (no) Farmasöytiske kombinasjoner
NO20033205D0 (no) Terapeutiske kromanforbindelser
NO20035627D0 (no) Farmasöytisk formulering
DE50209245D1 (de) Neuroprotektives medikament
FI20022128A (fi) Farmaseuttinen koostumus
NO20035352L (no) Legemidler for eosinofile sykdommer
NO20031650L (no) Nye legemidler for leversykdommer
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
NO20041236L (no) Farmasoytisk formulering
SE0103116D0 (sv) Pharmaceutical combination
SE0102823D0 (sv) New drug
SE0100007D0 (sv) Therapeutic compounds
SE0100008D0 (sv) Therapeutic compounds
SE0100006D0 (sv) Therapeutic compounds
SE0100009D0 (sv) Therapeutic compounds
FI5468U1 (fi) Farmaseuttinen koostumus
DK1330280T3 (da) Lægemiddelinhalator
UA5530S (uk) Таблетка фармацевтична
SE0102714D0 (sv) Artikulator

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application